Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Gains from Sales and Divestitures (2020 - 2023)

Terns Pharmaceuticals' Gains from Sales and Divestitures history spans 3 years, with the latest figure at $34762.0 for Q3 2023.

  • For Q3 2023, Gains from Sales and Divestitures changed N/A year-over-year to $34762.0; the TTM value through Sep 2023 reached $34762.0, changed N/A, while the annual FY2021 figure was $71429.0, 14.28% down from the prior year.
  • Gains from Sales and Divestitures reached $34762.0 in Q3 2023 per TERN's latest filing, up from $27055.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $83333.0 in Q4 2020 to a low of $27055.0 in Q2 2023.
  • Average Gains from Sales and Divestitures over 3 years is $59906.2, with a median of $71429.0 recorded in 2021.
  • The largest YoY upside for Gains from Sales and Divestitures was 14.28% in 2021 against a maximum downside of 14.28% in 2021.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $83333.0 in 2020, then fell by 14.28% to $71429.0 in 2021, then crashed by 51.33% to $34762.0 in 2023.
  • Per Business Quant, the three most recent readings for TERN's Gains from Sales and Divestitures are $34762.0 (Q3 2023), $27055.0 (Q2 2023), and $71429.0 (Q4 2021).